The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 15, 2022

Filed:

May. 15, 2018
Applicant:

Byondis B.v., Nijmegen, NL;

Inventors:

Gijsbertus Franciscus Maria Verheijden, Nijmegen, NL;

Gerard Rouwendal, Nijmegen, NL;

Roland Jan Arends, Nijmegen, NL;

Timo Kars Van Den Berg, Amsterdam, NL;

Hanke Lottie Matlung, Amsterdam, NL;

Katarina Franke, Amsterdam, NL;

Assignee:

Byondis B.V., Nijmegen, NL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 45/06 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention relates to antibodies against SIRPα that are suitable for use in anti-cancer therapy. The invention further relates to the use of the anti-SIRPα antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapeutics. The anti-SIRPalpha antibodies described are more specific than known anti-SIRPalpha antibodies, whereas they show excellent affinity for both SIRPalpha1 and SIRPalphaBIT. In one embodiment the anti-SIRPalpha antibodies do not bind to SIRPgamma. In a second embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPbeta1v1. In a third embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPeta1v2. In a fourth embodiment, the anti-SIRPalpha antibodies do not bind to SIRPbeta1v1.


Find Patent Forward Citations

Loading…